Added to YB: 2026-09-18
Pitch date: 2026-09-15
CLLS [neutral]
Cellectis S.A.
Author Info
No bio for this author
Company Info
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
Market Cap
EUR 113.3M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.67
P/E
-2.40
EV/Sales
0.42
Sector
Biotechnology
Category
turnaround
KEDM Lite Vol. 29 - Cellectis S.A.
CLLS (quick overview): Revenue-generating Cellectis is abandoning its allogeneic CAR-T programs and pivoting fully to in vivo gene editing, concentrating resources on HEAL-101 for severe hypertriglyceridemia and HEAL-201 for severe hypercholesterolemia. The overhaul extends its cash runway into late 2028, while shares fell roughly 30% on the news; the resulting disruption might create an opportunity.
Read full article (1 min)